Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study

Table 3 Perioperative and pathologic characteristics

	Before PSM			After PSM
	HCC (n = 141)	cHCC-CC (n = 111)	P value	HCC (n = 70)	cHCC-CC (n = 70)	P value
Perioperative
Operation (LDLT)	141 (100)	95 (85.6)	< 0.001	70 (100)	57 (44.9)	< 0.001
ABO-incompatibility	35 (24.8)	8 (7.2)	< 0.001	17 (24.3)	7 (10.0)	0.042
Macro-steatosis (%)	5 (0-20)	3 (0-30)	< 0.001	5 (1-20)	5 (0-30)	0.062
Micro-steatosis (%)	5 (1-70)	1 (0-90)	< 0.001	5 (1-40)	3 (0-90)	< 0.001
GRWR (%)	1.00 (0.65-1.71)	1.11 (0.67-3.89)	0.001	0.94 (0.67-1.70)	1.15 (0.67-3.89)	< 0.001
Cold ischemic time (min)	89 (45-168)	97 (30-1414)	0.029	95 (47-144)	97 (30-1414)	0.185
Warm ischemic time (min)	37 (16-81)	44 (20-90)	< 0.001	37 (17-81)	45 (22-87)	0.002
Operation time (min)	550 (336-960)	664 (270-1265)	< 0.001	544 (336-838)	639 (270-1265)	0.006
Hospitalization stay (d)	25 (17-445)	23 (4-262)	0.008	25 (17-94)	24 (4-262)	0.321
In-hospital mortality	2 (1.4)	4 (3.6)	0.41	1 (1.4)	4 (5.7)	0.366
Pathology
Tumor size > 3 cm	34 (24.3)	43 (38.7)	0.019	26 (37.1)	22 (31.4)	0.593
Tumor number > 3	22 (15.6)	28 (25.2)	0.079	13 (18.6)	20 (28.6)	0.232
Beyond Milan criteria	47 (33.3)	45 (40.5)	0.292	29 (41.4)	28 (40.0)	0.863
Tumor grade 3 or 4	19 (13.5)	33 (29.7)	0.002	10 (14.3)	14 (20.0)	0.502
Encapsulation	36 (25.5)	31 (27.9)	0.67	17 (24.3)	18 (25.7)	0.895
Tumor necrosis	55 (39.0)	55 (49.5)	0.098	24 (34.3)	38 (54.3)	0.027
Microvascular invasion	57 (40.4)	32 (28.8)	0.064	33 (47.1)	15 (21.4)	0.002
PVTT	7 (5.0)	15 (13.5)	0.023	4 (5.7)	7 (10.0)	0.532
BDTT	3 (2.1)	3 (2.7)	0.766	3 (4.3)	2 (2.9)	0.649
Intrahepatic metastasis	34 (24.1)	19 (17.1)	0.213	20 (28.6)	13 (18.6)	0.232
Multicentric occurrence	34 (24.1)	27 (24.3)	0.969	19 (27.1)	16 (22.9)	0.697
Lymph node metastasis	0 (0)	3 (2.7)	0.084	0 (0)	1 (1.4)	0.316

Data are presented as n (%) or median (range). LDLT: Living donor liver transplantation; GRWR: Graft-to-weight ratio; PVTT: Portal vein tumor thrombosis; BDTT: Bile duct tumor thrombosis; HCC: Hepatocellular carcinoma; PSM: Propensity score matching; cHCC-CC: Combined hepatocellular carcinoma and cholangiocarcinoma.